Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X about a recent paper by Florentine Hilbers et al. published in NPJ Breast Cancer:

“Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative Breast Cancer.

In clinically low-risk (T<1cm, N0) HR+/HER2- patients, there is no benefit of adjuvant chemotherapy in genomically high-risk patients according to MammaPrint.”

“Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers”

Authors: Florentine Hilbers, Coralie Poncet, Konstantinos Tryfonidis, Laura van ’t Veer, Fatima Cardoso et al.

Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer